MAPK7 and melanoma: Additionally, NRAS-mutant melanoma cells showed a proliferative advantage when, in response to MEK inhibitors treatment, expressed high levels of active ERK5 and the high rate of ERK5 was correlated with nuclear localization of the stem-like factor KLF2 [43].